RESUMEN
Duchenne muscular dystrophy is a genetic disorder that shows chronic and progressive damage to skeletal and cardiac muscle leading to premature death. Antiinflammatory corticosteroids targeting the glucocorticoid receptor (GR) are the current standard of care but drive adverse side effects such as deleterious bone loss. Through subtle modification to a steroidal backbone, a recently developed drug, vamorolone, appears to preserve beneficial efficacy but with significantly reduced side effects. We use combined structural, biophysical, and biochemical approaches to show that loss of a receptor-ligand hydrogen bond drives these remarkable therapeutic effects. Moreover, vamorolone uniformly weakens coactivator associations but not corepressor associations, implicating partial agonism as the main driver of its dissociative properties. Additionally, we identify a critical and evolutionarily conserved intramolecular network connecting the ligand to the coregulator binding surface. Interruption of this allosteric network by vamorolone selectively reduces GR-driven transactivation while leaving transrepression intact. Our results establish a mechanistic understanding of how vamorolone reduces side effects, guiding the future design of partial agonists as selective GR modulators with an improved therapeutic index.
Asunto(s)
Distrofia Muscular de Duchenne/tratamiento farmacológico , Pregnadienodioles/administración & dosificación , Pregnadienodioles/química , Humanos , Enlace de Hidrógeno , Ligandos , Distrofia Muscular de Duchenne/genética , Distrofia Muscular de Duchenne/metabolismo , Unión Proteica , Receptores de Glucocorticoides/química , Receptores de Glucocorticoides/genética , Receptores de Glucocorticoides/metabolismoRESUMEN
To discover new pharmacologically active natural products, here, we performed the phytochemical analysis of a Korean medicinal plant. Euonymus alatus (Thunb.) Sieb. is a traditional medicinal plant that has been used as a remedy for various diseases in Asian countries. In particular, the cork cambium on the twigs of E. alatus has been used to treat dysmenorrhea, tumors, diabetes, and wound. Phytochemical analysis of the methanolic extract of E. alatus twigs led to the isolation of a sterol, which was identified as (3ß,16α)-3,16-dihydroxypregn-5-en-20-one (1) by 1D and 2D nuclear magnetic resonance (NMR) spectroscopy and high-resolution electrospray ionization mass spectrometry. The stereochemistry of 1 was established with nuclear Overhauser effect spectroscopy (NOESY) analysis and comparison of electronic circular dichroism (ECD) data. To the best of our knowledge, the isolation of compound 1 from nature is first reported here, as well as the complete and revised NMR data assignment of 1. In lipopolysaccharide (LPS)-stimulated RAW-264.7 macrophages, compound 1 significantly inhibited nitric oxide (NO) production at an IC50 value of 12.54 ± 0.05 µM as well as the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Moreover, the pre-treatment with compound 1 attenuated the LPS-induced phosphorylation of nuclear factor kappa B (NF-κB) p65 through the inhibition of the phosphorylation of IκB kinase alpha (IKKα), IKKß, and inhibitor of kappa B alpha (IκBα). Compound 1 also inhibited the LPS-induced phosphorylation of p38, c-Jun NH2-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK). Taken together, compound 1 may serve as an anti-inflammatory constituent of E. alatus twigs and its anti-inflammatory property is thought to be associated with the inhibition of NO production via suppression of iNOS and COX-2 expression through inhibition of IKKα/ß, I-κBα and NF-κB p65 activation and downregulation of p38, JNK, and ERK mitogen-activated protein kinase signal pathways in RAW 264.7 macrophages. These findings also provide experimental evidence that compound 1 identified from E. alatus twigs could be a candidate for an anti-inflammatory agent.
Asunto(s)
Antiinflamatorios/farmacología , Euonymus/química , Inflamación/tratamiento farmacológico , Pregnadienodioles/farmacología , Animales , Antiinflamatorios/química , Antiinflamatorios/aislamiento & purificación , Dicroismo Circular , Ciclooxigenasa 2/genética , Expresión Génica/efectos de los fármacos , Humanos , Quinasa I-kappa B/genética , Inflamación/inducido químicamente , Inflamación/genética , Lipopolisacáridos/toxicidad , Espectroscopía de Resonancia Magnética , Ratones , Óxido Nítrico/antagonistas & inhibidores , Óxido Nítrico/biosíntesis , Óxido Nítrico Sintasa de Tipo II/genética , Pregnadienodioles/química , Pregnadienodioles/aislamiento & purificación , Células RAW 264.7 , Proteínas Quinasas p38 Activadas por Mitógenos/genéticaRESUMEN
Cardiomyopathy is a leading cause of death for Duchenne muscular dystrophy. Here, we find that the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) can share common ligands but play distinct roles in dystrophic heart and skeletal muscle pathophysiology. Comparisons of their ligand structures indicate that the Δ9,11 modification of the first-in-class drug vamorolone enables it to avoid interaction with a conserved receptor residue (N770/N564), which would otherwise activate transcription factor properties of both receptors. Reporter assays show that vamorolone and eplerenone are MR antagonists, whereas prednisolone is an MR agonist. Macrophages, cardiomyocytes, and CRISPR knockout myoblasts show vamorolone is also a dissociative GR ligand that inhibits inflammation with improved safety over prednisone and GR-specific deflazacort. In mice, hyperaldosteronism activates MR-driven hypertension and kidney phenotypes. We find that genetic dystrophin loss provides a second hit for MR-mediated cardiomyopathy in Duchenne muscular dystrophy model mice, as aldosterone worsens fibrosis, mass and dysfunction phenotypes. Vamorolone successfully prevents MR-activated phenotypes, whereas prednisolone activates negative MR and GR effects. In conclusion, vamorolone targets dual nuclear receptors to treat inflammation and cardiomyopathy with improved safety.
Asunto(s)
Antiinflamatorios/uso terapéutico , Cardiomiopatías/tratamiento farmacológico , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Miocarditis/tratamiento farmacológico , Pregnadienodioles/uso terapéutico , Receptores de Glucocorticoides/efectos de los fármacos , Receptores de Mineralocorticoides/efectos de los fármacos , Aldosterona/química , Aldosterona/farmacología , Aldosterona/uso terapéutico , Animales , Antiinflamatorios/química , Antiinflamatorios/farmacología , Proteína 9 Asociada a CRISPR/genética , Simulación por Computador , Modelos Animales de Enfermedad , Eplerenona/química , Eplerenona/farmacología , Eplerenona/uso terapéutico , Técnicas de Inactivación de Genes , Enlace de Hidrógeno , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones , Ratones Endogámicos C57BL , Antagonistas de Receptores de Mineralocorticoides/química , Antagonistas de Receptores de Mineralocorticoides/farmacología , Distrofia Muscular de Duchenne/tratamiento farmacológico , Miocarditis/metabolismo , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/metabolismo , Prednisolona/química , Prednisolona/farmacología , Prednisolona/uso terapéutico , Pregnadienodioles/química , Pregnadienodioles/farmacología , Células RAW 264.7 , Receptores de Glucocorticoides/química , Receptores de Glucocorticoides/genética , Receptores de Mineralocorticoides/agonistas , Receptores de Mineralocorticoides/químicaRESUMEN
Nasal deposition studies can demonstrate whether nasal sprays treating allergic rhinitis and polyposis reach the ciliated posterior nasal cavity, where turbinate inflammation and other pathology occurs. However, quantifying nasal deposition is challenging, because in vitro tests do not correlate to human nasal deposition; gamma scintigraphy studies are thus used. For valid data, the radiolabel must distribute, as the drug, into different-sized droplets, remain associated with the drug in the formulation after administration, and not alter its deposition. Some nasal deposition studies have demonstrated this using homogenous solutions. However, most commercial nasal sprays are heterogeneous suspensions. Using mometasone furoate nasal suspension (MFS), we developed a technique to validate radiolabel deposition as a surrogate for nasal cavity drug deposition and characterized regional deposition and nasal clearance in humans. Mometasone furoate (MF) formulation was spiked with diethylene triamine pentacaetic acid. Both unlabeled and radiolabeled formulations (n = 3) were sprayed into a regionally divided nasal cast. Drug deposition was quantified by high pressure liquid chromatography within each region; radiolabel deposition was determined by gamma camera. Healthy subjects (n = 12) were dosed and imaged for six hours. Scintigraphic images were coregistered with magnetic resonance imaging scans to quantify anterior and posterior nasal cavity deposition and mucociliary clearance. The ratio of radiolabel to unlabeled drug was 1.05 in the nasal cast and regionally appeared to match, indicating that in vivo radiolabel deposition could represent drug deposition. In humans, MFS delivered 86% (9.2) of metered dose to the nasal cavity, approximately 60% (9.1) of metered dose to the posterior nasal cavity. After 15 minutes, mucociliary clearance removed 59% of the initial radiolabel in the nasal cavity, consistent with clearance rates from the ciliated posterior surface. MFS deposited significant drug into the posterior nasal cavity. Both nasal cast validation and mucociliary clearance confirm the radiolabel deposition distribution method accurately represented corticosteroid nasal deposition.
Asunto(s)
Antialérgicos/administración & dosificación , Antialérgicos/farmacocinética , Rociadores Nasales , Pregnadienodioles/administración & dosificación , Pregnadienodioles/farmacocinética , Adulto , Antialérgicos/efectos adversos , Antialérgicos/química , Química Farmacéutica , Femenino , Humanos , Marcaje Isotópico , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Furoato de Mometasona , Depuración Mucociliar , Pregnadienodioles/efectos adversos , Pregnadienodioles/química , Cintigrafía , Adulto JovenRESUMEN
A set of solanidine analogs with antiproliferative properties were recently synthetized from pregnadienolone acetate, which occurs in Nature. The aim of the present study was an in vitro characterization of their antiproliferative action and an investigation of their multidrug resistance-reversal activity on cancer cells. Six of the compounds elicited the accumulation of a hypodiploid population of HeLa cells, indicating their apoptosis-inducing character, and another one caused cell cycle arrest at the G2/M phase. The most effective agents inhibited the activity of topoisomerase I, as evidenced by plasmid supercoil relaxation assays. One of the most potent analogs down-regulated the expression of cell-cycle related genes at the mRNA level, including tumor necrosis factor alpha and S-phase kinase-associated protein 2, and induced growth arrest and DNA damage protein 45 alpha. Some of the investigated compounds inhibited the ABCB1 transporter and caused rhodamine-123 accumulation in murine lymphoma cells transfected by human MDR1 gene, expressing the efflux pump (L5178). One of the most active agents in this aspect potentiated the antiproliferative action of doxorubicin without substantial intrinsic cytostatic capacity. The current results indicate that the modified solanidine skeleton is a suitable substrate for the rational design and synthesis of further innovative drug candidates with anticancer activities.
Asunto(s)
Diosgenina/química , Diosgenina/farmacología , Resistencia a Antineoplásicos/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Acetatos/química , Animales , Apoptosis/efectos de los fármacos , Puntos de Control del Ciclo Celular/efectos de los fármacos , Diosgenina/síntesis química , Doxorrubicina/química , Doxorrubicina/uso terapéutico , Células HeLa , Humanos , Ratones , Neoplasias/patología , Pregnadienodioles/síntesis química , Pregnadienodioles/químicaRESUMEN
Two new unusual cholestane derivatives, pentacyclic steroid 16,22-epoxy-20ß,23S-dihydroxycholest-1-ene-3-one (1) and 20ß,23S-dihydroxycholest-1-ene-3,22-dione (2), along with two new pregnane derivatives, 15ß,17α-dihydroxypregna-4,6-diene-3,20-dione (3) and 11α-hydroxypregna-4-ene-3,6,20-trione (4), were isolated from the South China Sea gorgonian coral Subergorgia suberosa. Their structures were established based on the extensive analyses of 2D NMR, IR, and HRMS. Antifouling tests against Balanus amphitrite larvae settlement indicated that 1 and 2 exhibited inhibitory effect with EC50 values of 5.3, and 14.5 µg/mL, respectively.
Asunto(s)
Antozoos/química , Incrustaciones Biológicas/prevención & control , Esteroides/química , Esteroides/farmacología , Animales , Colestanos/química , Colestanos/farmacología , Colestenonas/química , Colestenonas/farmacología , Relación Dosis-Respuesta a Droga , Larva/efectos de los fármacos , Larva/crecimiento & desarrollo , Espectroscopía de Resonancia Magnética/métodos , Espectrometría de Masas , Estructura Molecular , Océanos y Mares , Prednisona/análogos & derivados , Prednisona/química , Prednisona/farmacología , Pregnadienodioles/química , Pregnadienodioles/farmacología , Pregnanos/química , Pregnanos/farmacología , Espectrofotometría , Estereoisomerismo , Thoracica/efectos de los fármacos , Thoracica/crecimiento & desarrolloRESUMEN
The objective of this study was to investigate the feasibility of microdialysis as a tool to determine the skin concentration of mometason furoate (MF), a lipophilic and highly protein-bound compound. The relative recovery (RR) of mometasone furoate was determined by an in vitro no-net-flux method using three different perfusates (40% PEG400, 5% fat emulsion, and 20% fat emulsion) and four flow rates (0.5, 1, 2, and 4 µL x min(-1)). With the increasing of flow rate, the relative recovery was decreased from 48.8% to 3.1%. The in vitro recovery was increased to 23.71%, 42.76% and 56.21% when 40% PEG400, 5% fat emulsion or 20% fat emulsion was used as microdialysis perfusates, respectively. Fat emulsion (5%) was chosen as the perfusate to evaluate the in vivo recovery by a retrodialysis method, in which mometasone furoate concentration in different tissues was determined. The result showed that concentrations of mometasone furoate in the dermis was greater than that in the subcutaneous or muscle tissue. It was concluded that a recovery enhancer could be used in microdialysis technique, especially for determining skin concentrations of lipophilic and high protein-bounds.
Asunto(s)
Antiinflamatorios/análisis , Microdiálisis/métodos , Pregnadienodioles/análisis , Piel/química , Animales , Antiinflamatorios/química , Antiinflamatorios/farmacocinética , Cromatografía Líquida de Alta Presión , Masculino , Furoato de Mometasona , Pregnadienodioles/química , Pregnadienodioles/farmacocinética , Ratas , Ratas Wistar , Solubilidad , Espectrofotometría Ultravioleta , Distribución TisularRESUMEN
Asthma is a chronic inflammatory condition of the lower respiratory tract associated with airway hyperreactivity and mucus obstruction in which a majority of cases are due to an allergic response to environmental allergens. Glucocorticoids such as prednisone have been standard treatment for many inflammatory diseases for the past 60 years. However, despite their effectiveness, long-term treatment is often limited by adverse side effects believed to be caused by glucocorticoid receptor-mediated gene transcription. This has led to the pursuit of compounds that retain the anti-inflammatory properties yet lack the adverse side effects associated with traditional glucocorticoids. We have developed a novel series of steroidal analogues (VBP compounds) that have been previously shown to maintain anti-inflammatory properties such as NFκB-inhibition without inducing glucocorticoid receptor-mediated gene transcription. This study was undertaken to determine the effectiveness of the lead compound, VBP15, in a mouse model of allergic lung inflammation. We show that VBP15 is as effective as the traditional glucocorticoid, prednisolone, at reducing three major hallmarks of lung inflammation--NFκB activity, leukocyte degranulation, and pro-inflammatory cytokine release from human bronchial epithelial cells obtained from patients with asthma. Moreover, we found that VBP15 is capable of reducing inflammation of the lung in vivo to an extent similar to that of prednisone. We found that prednisolone--but not VBP15 shortens the tibia in mice upon a 5 week treatment regimen suggesting effective dissociation of side effects from efficacy. These findings suggest that VBP15 may represent a potent and safer alternative to traditional glucocorticoids in the treatment of asthma and other inflammatory diseases.
Asunto(s)
Glucocorticoides/uso terapéutico , Hipersensibilidad/complicaciones , Hipersensibilidad/tratamiento farmacológico , Neumonía/complicaciones , Neumonía/tratamiento farmacológico , Pregnadienodioles/uso terapéutico , Animales , Asma/complicaciones , Asma/metabolismo , Asma/patología , Degranulación de la Célula/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Citocinas/metabolismo , Modelos Animales de Enfermedad , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Células Epiteliales/patología , Femenino , Glucocorticoides/química , Glucocorticoides/farmacología , Humanos , Leucocitos/efectos de los fármacos , Leucocitos/fisiología , Pulmón/efectos de los fármacos , Pulmón/patología , Masculino , Ratones , Ratones Endogámicos BALB C , FN-kappa B/metabolismo , Osteogénesis/efectos de los fármacos , Ovalbúmina , Pregnadienodioles/química , Pregnadienodioles/farmacología , Tibia/efectos de los fármacos , Tibia/patologíaRESUMEN
Δ9,11 modifications of glucocorticoids (21-aminosteroids) have been developed as drugs for protection against cell damage (lipid peroxidation; lazaroids) and inhibition of neovascularization (anecortave). Part of the rationale for developing these compounds has been the loss of glucocorticoid receptor binding due to the Δ9,11 modification, thus avoiding many immunosuppressive activities and deleterious side effect profiles associated with binding to glucocorticoid and mineralocorticoid receptors. We recently demonstrated that anecortave acetate and its 21-hydroxy analog (VBP1) do, in fact, show glucocorticoid and mineralocorticoid receptor binding activities, with potent translocation of the glucocorticoid receptor to the cell nucleus. We concluded that Δ9,11 steroids showed novel anti-inflammatory properties, retaining NF-κB inhibition, but losing deleterious glucocorticoid side effect profiles. Evidence for this was developed in pre-clinical trials of chronic muscle inflammation. Here, we describe a drug development program aimed at optimizing the Δ9,11 chemistry. Twenty Δ9,11 derivatives were tested in in vitro screens for NF-κB inhibition and GR translocation to the nucleus, and low cell toxicity. VBP15 was selected as the lead compound due to potent NF-κB inhibition and GR translocation similar to prednisone and dexamethasone, lack of transactivation properties, and good bioavailability. Phamacokinetics were similar to traditional glucocorticoid drugs with terminal half-life of 0.35 h (mice), 0.58 h (rats), 5.42 h (dogs), and bioavailability of 74.5% (mice), and 53.2% (dogs). Metabolic stability showed ≥80% remaining at 1 h of VBP6 and VBP15 in human, dog, and monkey liver microsomes. Solubility, permeability and plasma protein binding were within acceptable limits. VBP15 moderately induced CYP3A4 across the three human hepatocyte donors (24-42%), similar to other steroids. VBP15 is currently under development for treatment of Duchenne muscular dystrophy.
Asunto(s)
Antiinflamatorios/farmacología , FN-kappa B/antagonistas & inhibidores , Pregnadienodioles/farmacología , Animales , Antiinflamatorios/química , Núcleo Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Perros , Evaluación Preclínica de Medicamentos , Glucocorticoides/química , Glucocorticoides/farmacología , Haplorrinos , Humanos , Masculino , Ratones , Pregnadienodioles/química , RatasRESUMEN
Inhaled corticosteroids administered by dry powder inhaler (DPI) or metered-dose inhaler are potent anti-inflammatory agents recommended for management of persistent asthma. Respiratory pharmacotherapy is unique in that proper delivery of the medication can be as important as the medication that is delivered. This study was designed to assess the mass median aerodynamic diameter (MMAD) of mometasone furoate (MF) particles from the 100- and 200-microgram/inhalation strength Twisthhaler (Merck & Co., Inc., Whitehouse Station, NJ) and to examine clinical effects of MF-DPI on midexpiratory flow. The MMAD with 100- and 200-microgram Twisthaler inhalers was analyzed using an Anderson cascade impactor. Clinical trial data for MF-DPI administered q.d. in the evening (P.M.) in adults and adolescents aged ≥12 years, as well as children aged 4-11 years, were examined post hoc for changes in forced expiratory flow between 25 and 75% of vital capacity (FEF(25-75)). The average MMAD of the 100-microgram strength Twisthaler (n = 24) was 2.0 micrometers; the average MMAD of the 200-microgram strength Twisthaler (n = 24) was 2.2 micrometers. In adults and adolescents (n = 1149), significant improvements in FEF(25-75) occurred with MF-DPI administered q.d. P.M. versus placebo (p ≤ 0.05). In children (n = 296), FEF(25-75) improved significantly with MF-DPI at 100 microgram q.d. P.M. versus placebo at day 4 and every visit thereafter (p ≤ 0.05). In vitro study suggests that the particle size of MF is optimal (~2 micrometers) for efficient lung deposition when administered via the Twisthaler. Furthermore, randomized, controlled trials provide clinical evidence that MF-DPI q.d. treatment improves small airway function in patients with mild persistent or moderate asthma.
Asunto(s)
Antialérgicos/administración & dosificación , Inhaladores de Polvo Seco , Hipersensibilidad/tratamiento farmacológico , Pregnadienodioles/administración & dosificación , Adolescente , Adulto , Aerosoles , Antialérgicos/química , Niño , Preescolar , Sistemas de Liberación de Medicamentos , Femenino , Humanos , Masculino , Flujo Espiratorio Medio Máximo , Furoato de Mometasona , Tamaño de la Partícula , Pregnadienodioles/química , Sistema Respiratorio/efectos de los fármacosRESUMEN
Glaucoma and age-related macular degeneration are ocular diseases targeted clinically by anecortave acetate (AA). AA and its deacetylated metabolite, anecortave desacetate (AdesA), are intraocular pressure (IOP)-lowering and angiostatic cortisenes devoid of glucocorticoid activity but with an unknown mechanism of action. We used a methotrexate-anchored yeast three-hybrid (Y3H) technology to search for binding targets for AA in human trabecular meshwork (TM) cells, the target cell type that controls IOP, a major risk factor in glaucoma. Y3H hits were filtered by competitive Y3H screens and coimmunoprecipitation experiments and verified by surface plasmon resonance analysis to yield a single target, phosphodiesterase 6-delta (PDE6D). PDE6D is a prenyl-binding protein with additional function outside the PDE6 phototransduction system. Overexpression of PDE6D in mouse eyes caused elevated IOP, and this elevation was reversed by topical ocular application of either AA or AdesA. The identification of PDE6D as the molecular binding partner of AA provides insight into the role of this drug candidate in treating glaucoma.
Asunto(s)
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 6/antagonistas & inhibidores , Metotrexato/metabolismo , Pregnadienodioles/farmacología , Técnicas del Sistema de Dos Híbridos , Animales , Línea Celular , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 6/biosíntesis , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 6/metabolismo , Ensayos Analíticos de Alto Rendimiento , Humanos , Metotrexato/química , Ratones , Ratones Endogámicos BALB C , Estructura Molecular , Pregnadienodioles/química , Relación Estructura-ActividadRESUMEN
Engineered porous phospholipid microparticles with aerodynamic diameters in the respirable range of 1-2 µm were cosuspended in 1,1,1,2-tetrafluoroethane, a propellant, with microcrystals of glycopyrrolate, formoterol fumarate dihydrate, or Mometasone furoate-three drugs with different solubilities in the propellant, and different physical, chemical, and pharmacological attributes. The drug microcrystals were added individually, in pairs, or all three together to prepare different cosuspensions, contained in a pressurized metered dose inhaler (pMDI). The drug microcrystals irreversibly associated with the porous particles, and the resultant cosuspensions possessed greatly improved suspension stability compared with suspensions of drug microcrystals alone. In general, all cosuspensions showed efficient dose delivery of the drugs, with fine particle fractions of more than 60% for a wide range of doses, including those as low as 300 ng per inhaler actuation. In the cosuspension pMDIs, comparable fine particle fractions were delivered for all tested drugs, whether or not they were emitted from an inhaler containing one, two, or three drugs. We demonstrate that the cosuspension approach solves at least three long-standing problems in the clinical development of pMDI-based products: (1) dose and drug dependent delivery efficiency, (2) inability to formulate dose strengths below 1 µg to fully explore drug efficacy and safety, and (3) combination suspensions delivering a different fine particle fraction than individual drug suspensions.
Asunto(s)
Etanolaminas/química , Fumaratos/química , Glicopirrolato/química , Inhaladores de Dosis Medida , Fosfolípidos/química , Pregnadienodioles/química , Terapia Respiratoria , Sistemas de Liberación de Medicamentos , Fumarato de Formoterol , Hidrocarburos Fluorados/química , Furoato de Mometasona , Tamaño de la Partícula , Porosidad , Solubilidad , Propiedades de Superficie , Agua/químicaRESUMEN
Steroid receptors (SRs) are the largest family of metazoan transcription factors and control genes involved in development, endocrine signaling, reproduction, immunity, and cancer. The entire hormone receptor system is driven by a molecular switch triggered by the binding of small lipophilic ligands. This makes the SRs ideal pharmaceutical targets, yet even the best clinically approved synthetic steroidal agonists are prone to cross-reactivity and off-target pharmacology. The mechanism underlying this promiscuity is derived from the fact that SRs share common structural features derived from their evolutionary relationship. More often than not, rational attempts to probe SR drug selectivity via mutagenesis fail even when high quality structural and functional data are available due to the fact that important mutations often result in nonfunctional receptors. This highlights the fact that SRs suffer from instability, preventing in-depth mutational analysis and hampering crystallization of key receptor-ligand complexes. We have taken a unique approach to address this problem by using a resurrected ancestral protein to determine the structure of a previously intractable complex and identified the structural mechanisms that confer activation and selectivity for a widely used glucocorticoid, mometasone furoate. Moreover, we have identified a single residue located outside of the ligand-binding pocket that controls mometasone furoate antagonism versus agonism in the human mineralocorticoid receptor.
Asunto(s)
Pregnadienodioles/química , Receptores de Mineralocorticoides/química , Sitios de Unión/genética , Cristalografía por Rayos X , Humanos , Furoato de Mometasona , Mutagénesis , Receptores de Mineralocorticoides/agonistas , Receptores de Mineralocorticoides/genética , Receptores de Mineralocorticoides/metabolismoRESUMEN
Mometasone furoate, a potent glucocorticoid (class III) with a favorable benefit/risk ratio, has emerged as a standard medication for the treatment of inflammatory skin disorders. The purpose of the investigation presented here was to determine the noninferiority of a topical mometasone formulation, a light cream (O/W 60/40 emulsion) with mometasone furoate 0.1% (water content of 33%) versus marketed comparators. Using the vasoconstrictor assay, a strong blanching effect of the new cream (called Mometasone cream) comparable to that of a mometasone comparator, a fatty cream with mometasone furoate 0.1%, could be demonstrated. Thus, the topical bioavailability of the active ingredient mometasone furoate (0.1%) was regarded to be similar for Mometasone cream and the mometasone comparator. Using the psoriasis plaque test, a strong antipsoriatic effect comparable to that of the mometasone comparator was found for Mometasone cream after 12 days of occlusive treatment. A nearly identical reduction in the mean infiltrate thickness and similar mean AUC values were noted with both formulations confirmed by clinical assessment data. The noninferiority of Mometasone cream to its active comparator with respect to the AUC of change to baseline in infiltrate thickness was demonstrated. Both medications were well tolerated. Overall, Mometasone cream and the mometasone comparator showed similar efficacy and tolerability. Mometasone cream, in addition to its high potency and good tolerability, provides the properties of a light cream, which might make this new medication particularly suitable for application on acutely inflamed and sensitive skin.
Asunto(s)
Fármacos Dermatológicos/farmacocinética , Glucocorticoides/farmacocinética , Pregnadienodioles/farmacocinética , Psoriasis/tratamiento farmacológico , Absorción Cutánea , Piel/efectos de los fármacos , Piel/metabolismo , Administración Cutánea , Adolescente , Adulto , Anciano , Área Bajo la Curva , Disponibilidad Biológica , Química Farmacéutica , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Fármacos Dermatológicos/química , Método Doble Ciego , Femenino , Alemania , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Glucocorticoides/química , Humanos , Masculino , Persona de Mediana Edad , Furoato de Mometasona , Pomadas , Pregnadienodioles/administración & dosificación , Pregnadienodioles/efectos adversos , Pregnadienodioles/química , Psoriasis/patología , Piel/irrigación sanguínea , Piel/patología , Vasoconstricción/efectos de los fármacos , Adulto JovenRESUMEN
Polyoxazolines with a biocidal quarternary ammonium end-group are potent biocides. Interestingly, the antimicrobial activity of the whole macromolecule is controlled by the nature of the group at the distal end. These nonreactive groups are usually introduced via the initiator. Here we present a study with a series of polymethyloxazolines with varying satellite groups introduced upon termination of the polymerization reaction. This allowed us to introduce a series of functional satellites, including hydroxy, primary amino, and double-bond-containing groups. The resulting telechelic polyoxazolines were explored regarding their antimicrobial activity and toxicity. It was found that the functional satellite groups greatly controlled the minimal inhibitory concentrations against the bacteria Staphylococcus aureus and Escherichia coli in a range of 10 to 2500 ppm. Surprisingly, the satellite groups also controlled the hemotoxicity but in a different way than the antimicrobial efficiency.
Asunto(s)
Antiinfecciosos , Eritrocitos , Escherichia coli/crecimiento & desarrollo , Hemólisis/efectos de los fármacos , Pregnadienodioles , Staphylococcus aureus/crecimiento & desarrollo , Animales , Antiinfecciosos/síntesis química , Antiinfecciosos/química , Antiinfecciosos/farmacología , Relación Dosis-Respuesta a Droga , Pregnadienodioles/síntesis química , Pregnadienodioles/química , Pregnadienodioles/farmacología , PorcinosRESUMEN
We have synthesized 3ß,21-dihydroxypregna-5,7-dien-20-one (21(OH) 7DHP) and used UVB radiation to induce its photoconversion to analogues of vitamin D (pD), lumisterol (pL) and tachysterol (pT). The number and character of the products and the dynamics of the process were dependent on the UVB dose. The main products: pD and pT compounds were characterized by UV absorption, MS and NMR spectroscopy after RP-HPLC chromatography. In addition, formation of multiple oxidized derivatives of the primary products was detected and one of these derivatives was characterized as oxidized 21-hydroxyisotachysterol compound (21(OH)oxy-piT). These newly synthesized compounds inhibited growth of human melanoma cells in a dose dependent manner, with greater or equal potency to calcitriol. 3ß,21-Dihydroxy-9ß,10α-pregna-5,7-dien-20-one (21(OH)pL) and 21(OH)oxy-piT had higher potency against pigmented melanoma cells, while the EC(50) for compounds 21(OH)7DHP and (5Z,7E)-3ß,21-dihydroxy-9,10-secopregna-5,7,10(19)-trien-20-one (21(OH)pD) were similar in both pigmented and non-pigmented cells. Moreover, 21(OH)7DHP and its derivatives inhibited proliferation of human epidermal HaCaT keratinocytes, albeit at a lower activity compared to melanoma cells. Importantly, 21(OH)7DHP derivatives strongly inhibited the colony formation of human melanoma cells with 21(OH)pD being the most potent. The potential mechanism of action of newly synthesized compounds was similar to that mediated by 1,25(OH)(2)D(3) and involved ligand-induced translocation of vitamin D receptor into the nucleus. In summary, we have characterized for the first time products of UVB-induced conversion of 21(OH)7DHP and documented that these compounds have selective, inhibitory effects on melanoma cells.
Asunto(s)
Antineoplásicos/farmacología , Melanoma/tratamiento farmacológico , Pregnadienodioles/farmacología , Secoesteroides/farmacología , Antineoplásicos/síntesis química , Antineoplásicos/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Melanoma/patología , Conformación Molecular , Fotoquímica , Pregnadienodioles/síntesis química , Pregnadienodioles/química , Secoesteroides/síntesis química , Secoesteroides/química , Estereoisomerismo , Rayos UltravioletaAsunto(s)
Histamina/efectos adversos , Hipersensibilidad Inmediata/tratamiento farmacológico , Pregnadienodioles/administración & dosificación , Ácido Salicílico/administración & dosificación , Administración Tópica , Química Farmacéutica , Quimioterapia Combinada , Histamina/administración & dosificación , Humanos , Hipersensibilidad Inmediata/inducido químicamente , Furoato de Mometasona , Pregnadienodioles/química , Ácido Salicílico/químicaRESUMEN
Inhaled corticosteroids (ICS) are recommended as a controller medication in the most recent Global Initiative for Asthma and the National Heart, Lung and Blood Institute guidelines. Mometasone furoate (MF) is an effective, well-tolerated inhaled steroid and is indicated for the maintenance treatment of adult and adolescent patients (> or = 12 years) with persistent asthma. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low systemic bioavailability and high relative binding affinity for the glucocorticoid receptor are properties of MF that allow for a favourable efficacy and tolerability profile. Inhaled MF has been shown to be an effective and well-tolerated controller medication for those patients with mild, moderate or severe persistent asthma. MF has recently been approved by the US regulatory authorities for use in children (4-11 years). Future developments include the combination of MF with the long-acting bronchodilators, formoterol and indacaterol, to provide additional options in the treatment of asthma.
Asunto(s)
Antiasmáticos/administración & dosificación , Antiinflamatorios/administración & dosificación , Asma/tratamiento farmacológico , Pregnadienodioles/administración & dosificación , Administración por Inhalación , Adolescente , Corticoesteroides/administración & dosificación , Adulto , Anciano , Antiasmáticos/efectos adversos , Antiasmáticos/química , Antiinflamatorios/efectos adversos , Antiinflamatorios/química , Disponibilidad Biológica , Niño , Preescolar , Humanos , Persona de Mediana Edad , Furoato de Mometasona , Pregnadienodioles/efectos adversos , Pregnadienodioles/química , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Adulto JovenRESUMEN
PURPOSE: To characterise the adhesive interactions between three pulmonary active pharmaceutical ingredient (API) materials and the components of pressurised metered dose inhalers (pMDIs) obtained from two commercially available products (termed 'Prod-1' and 'Prod-2'). This is of potential interest, as a greater understanding of the interactions between specific APIs and surfaces may aid manufacturers in component selection during pMDI system development. METHODS: The theoretical work of adhesion (DeltaG(132)) for each API-pMDI component interaction was calculated using the surface component analysis (SCA) approach. These results were correlated with corresponding API-pMDI component separation energy measurements determined using colloid probe AFM. RESULTS: Strong correlations existed between separation energy and the DeltaG(132) parameters where the polar contribution was accounted for. This highlighted the adhesive influence of polar surface energy on each interaction in this study. Generally the largest adhesive interactions involved APIs and pMDI components which have a bipolar surface energy (i.e. both gamma(-) and gamma(+) >1 mJ m(-2)). CONCLUSIONS: For each API-pMDI interaction in this study, the polar component of surface energy has the greater influence on adhesive events. The bipolar surface energetics of certain APIs and pMDI components were deemed responsible for the increased adhesive interactions observed with these materials. This study highlights that different materials can have different effects on the adhesive interactions with particulate APIs; information that could aid the manufacturer in producing more effective and efficient pMDI systems.
Asunto(s)
Elastómeros/química , Inhaladores de Dosis Medida , Microscopía de Fuerza Atómica/métodos , Polímeros/química , Adhesividad , Aerosoles , Albuterol/administración & dosificación , Albuterol/química , Antiinflamatorios/administración & dosificación , Antiinflamatorios/química , Broncodilatadores/administración & dosificación , Broncodilatadores/química , Calcitonina/administración & dosificación , Calcitonina/química , Química Farmacéutica , Furoato de Mometasona , Pregnadienodioles/administración & dosificación , Pregnadienodioles/química , Propiedades de Superficie/efectos de los fármacos , SuspensionesRESUMEN
An induced-fit docking method was used to characterize the interactions of the glucocorticoid receptor binding-site with mometasone furoate, a glucocorticoid with a lipophilic ester at the C17alpha position. Two validation studies demonstrated that the protocol can reproduce crystal structures of nuclear receptors, and is appropriate for modeling ligand binding to the glucocorticoid receptor. Key hydrogen bonding interactions between mometasone furoate and the glucocorticoid receptor, as well as favorable hydrophobic interactions between the furoate group and the 17alpha pocket, contribute to high affinity and specificity of this ligand for the receptor. Using the glucocorticoid des-ciclesonide, which has an even larger moiety at the 16,17alpha position, induced-fit docking demonstrates the ability of the 17alpha pocket of the receptor to expand even further to accommodate the ligand.